Abstract:Abstract Mammography screening is widely used for earlier detection of breast cancer and has been shown to contribute to reduction of mortality and morbidity. Most screen-detected breast cancers are early stage, hormonal receptor-positive, HER2-negative (HR+ HER2-) breast cancers. The majority of HR+ HER2- cancers are assigned to molecular intrinsic subtypes of Luminal A and Luminal B, which generally harbour low recurrence risk, with Luminal B cases being more invasive but still less aggressive than HER2-enriched or Basal-like subtypes. However, some of these Luminal cancers later recur (5+ years after diagnosis) often as advanced and/or metastatic disease. We studied a cohort of screen-detected breast cancers (42 cases) at Sunnybrook Health Sciences Centre (Toronto, ON Canada) with integrated cross-platform radiomics, molecular and proteomic analysis in an attempt to better characterise these cancers and their proclivity for late recurrence. Utilising a Nanostring 200-gene assay, the molecular subtypes (PAM50 and MammaTyper-like) and a range of recapitulated clinical prognostic scores (50-Gene, 70-Gene and 21-Gene Risk) were determined for these cancers. While a majority of cases (29 out of 42) were subtyped as Luminal A cancers by PAM50, a fraction (12 out of 29) of these were either subtyped as Luminal B/HER2+ based on MammaTyper-like results, or measured as intermediate to high risk of recurrence based on the 70-Gene or 21-Gene Risk classification. Although discordant results from multi-parametric assays are not uncommon, we postulate that here, discordance could suggest presence of heterogeneous cellular or molecular elements with invasive phenotype that could lead to aggressive transformations in the long run. Differential expression analysis between Luminal A cases with consistent subtyping and low risk prognostication and those with discordant subtyping or prognostication results revealed a panel of genes with significant changes in expression. Further analysis of RNA expression of these genes via Receiver Operating Characteristic (ROC) curve demonstrated that some genes showed high Area Under the Curve (AUC) scores in the classification between the two groups of Luminal A breast cancers, further supporting the existence of distinct molecular phenotypes. Targeted sequencing with Oncomine Comprehensive Assay V3 did not reveal particular mutational patterns between the two Luminal A groups. Nevertheless, radiomic analysis of mammographic images of the cancer, as well as single cell phenotyping of the tumor microenvironment with protein multiplexing will be incorporated to further characterise elements that are phenotypically different, and potentially identify mechanistic drivers contributing to late recurrence in Luminal A cancers. Citation Format: Alison M. Cheung, Dan Wang, Kela Liu, Yutaka Amemiya, Elzbieta Slodkowska, James G. Mainprize, Jane Bayani, Arun Seth, John Bartlett, Martin J. Yaffe. Integrative cross-platform characterisation of mammographic screen-detected breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5622.

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

Abstract 5622: Integrative cross-platform characterisation of mammographic screen-detected breast cancer

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Repeated observation of breast tumor subtypes in independent gene expression data sets

Clinical implications of the intrinsic molecular subtypes of breast cancer

Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups

Clinical features and survival analysis of molecular subtyping of breast cancer

Molecular Identification of Basal-Like Breast Cancer Through Genomic Analyses Across Five Cancer Types

A DNA methylation-based definition of biologically distinct breast cancer subtypes

Integrative Analysis Identifies Two Molecular and Clinical Subsets in Luminal B Breast Cancer

The Molecular Portraits of Breast Tumors Are Conserved Across Microarray Platforms

Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study

Differential Chromatin Accessibility and Transcriptional Dynamics Define Breast Cancer Subtypes and Their Lineages

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

Breast cancer prognosis signature: linking risk stratification to disease subtypes

Notch-associated Expression Profiles in Basal-Like and Claudin-Low Breast Cancer Molecular Subtypes

Differences in Risk Factors for Breast Cancer Molecular Subtypes in A Population-Based Study